Researchers in Japan have developed an experimental technique that exploits carbon monoxide produced by cancer cells to generate cancer-killing compounds from within the tumours themselves. The study, led by Katsunori Tanaka at the RIKEN Pioneering Research Institute (PRI), offers a potential alternative to conventional chemotherapy by targeting the unique metabolic environment of malignant cells.
The breakthrough, published in Nature Communications, addresses a fundamental challenge in oncology: the difficulty of distinguishing between cancerous and noncancerous cells. Traditional treatments often involve administering powerful drugs that circulate through the entire body, which can result in debilitating side effects such as nausea, fatigue, hair loss, and immune system suppression due to damage to healthy tissues.
Tanaka and his colleagues focused on carbon monoxide, a gas that is toxic in high concentrations but is naturally produced in small quantities by the human body. Their strategy involves delivering a metal-based catalyst into cells, which uses the available carbon monoxide as chemical fuel to manufacture an anticancer substance. Because cancer cells produce carbon monoxide in greater abundance, the reaction is designed to be activated predominantly in these malignant cells rather than in healthy tissues.
In laboratory experiments, the technique successfully generated toxic compounds in several cancer cell lines. Crucially, the same process did not produce detectable levels of the compound in a noncancerous cell line, demonstrating the method’s potential for selectivity. This approach transforms an unusual feature of cancer biology into a therapeutic advantage by allowing the body’s own cancerous cells to produce the agents that destroy them.
Implications for Future Treatments
While the findings are still at an early experimental stage, they represent a significant step in the field of therapeutic in vivo synthetic chemistry. This emerging scientific discipline seeks to use chemical reactions inside living organisms to manufacture therapeutic substances precisely where they are needed. By generating anticancer agents locally within tumours, this method could potentially spare healthy tissues from the collateral damage associated with current standard-of-care treatments.
<small>Source: Vanguard News — read the original story there.</small>
